Dr. Reddy’s Laboratories Ltd ADR (RDY)

60.52
-1.88(-3.01%)
After Hours
60.74
+0.21(+0.36%)
- Real-time Data
  • Volume:
    144,960
  • Bid/Ask:
    60.00/61.47
  • Day's Range:
    60.34 - 62.12

RDY Overview

Prev. Close
62.4
Day's Range
60.34-62.12
Revenue
2.59B
Open
61.85
52 wk Range
57.54-75.5
EPS
1.38
Volume
144,960
Market Cap
10.13B
Dividend (Yield)
0.32
(0.54%)
Average Vol. (3m)
120,292
P/E Ratio
45.35
Beta
0.46
1-Year Change
-8.12%
Shares Outstanding
165,906,146
Next Earnings Date
Feb 03, 2022
What is your sentiment on Dr. Reddy’s Laboratories Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

Dr. Reddy’s Laboratories Ltd ADR Company Profile

Employees
22739

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellNeutral
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellSell
  • Dr.Reddy lab ADR will cross 75 by end october 2021. Slow and steady safe bet.
    0
    • Buy Dr. Reddy around 63 target 65
      0
      • friends plz suggest DRREDDY will reach 52 week low
        0
        • NOT AT ALL
          0
      • pls suggest DRREDDY is short or long in short term
        0
        • long
          0
        • target
          0
      • first time ADR Green Bay Area
        0
        • I am having 5400ce at 150 August expiry any chance of recovery or shall I book the loss and exit. advice by the experts will be really appreciated. thanks
          0
          • 5-7 trading session target 5200....August expiry target 6000++++.sputnik v related news comes 15th August
            1
          • thanks alot dear for the update. Is the news is sureshot.
            1
          • it will move to 4400
            0
        • tomorrow drreddy ready to fly open 5100......5213....5326....5454....5500
          4
          • already adr has been down ...how can it open gapup
            0
        • Dr 89ko Chal pada
          0
          • DR WILL COME BY 10TH JUNE 5450
            0
            • Gabbu company no returns... Dm
              0
              • This stock never give good returns.. Only loss
                1
                • thanks to biden lift the ban on raw materials of export. US such a good supportive to India 2mrw pharma rocking
                  0
                  • girega yeh kal bhi dont worry.im 100% sure
                    0
                • it will crash buy puts
                  1
                  • never crash bro 2morrow you will see the indian market magic
                    0
                  • 6000 to 7000 will touch on this expiry
                    0
                • it's safe bet for 10% upside in short term
                  1
                  • it will fall now
                    0
                    • Target 70/72/75 Short term
                      1
                      • will be strong buy in india ,
                        0
                        • very attractive valuation...
                          0
                          • very attractive valuation...
                            0
                            • Finally Most awaited medicine Epilepsy of Dr Reddy available in the market.
                              0
                              • Russia's COVID-19 vaccine, Sputnik V is over 90 per cent effective, according to the Health Ministry. The Health Ministry cited data collected from public vaccinations rather than that of an ongoing trial. The comments from Russian health ministry followed the announcement by Pfizer and BioNTech, who also claimed that their vaccine candidate was more than 90 per cent effective. Oksana Drapkina, director of a research institute under the Russian health ministry said, "We are responsible for monitoring the effectiveness of the Sputnik V vaccine among citizens who have received it as part of the mass vaccination programme." Drapkina further added that the efficacy of the vaccine was more than 90 per cent.
                                2
                                • The president continued on by saying that all of Russia’s vaccines against COVID-19 are efficient. "We have two registered vaccines in Russia, and the trials have already confirmed that the vaccines are safe, there are no side effects, and they are efficient. A third vaccine is in the pipeline. They are effective, the people who have been vaccinated and who have then had contact with people who have contracted the coronavirus have not contracted the coronavirus themselves, or they only have mild symptoms", he said. Putin has also agreed with Pakistani Prime Minister Imran Khan that a COVID-19 vaccine should be a global public good. "I fully agree with you that the
                                  0
                                  • Russia's COVID-19 vaccine, Sputnik V is over 90 per cent effective, according to the Health Ministry. The Health Ministry cited data collected from public vaccinations rather than that of an ongoing trial. The comments from Russian health ministry followed the announcement by Pfizer and BioNTech, who also claimed that their vaccine candidate was more than 90 per cent effective. Oksana Drapkina, director of a research institute under the Russian health ministry said, "We are responsible for monitoring the effectiveness of the Sputnik V vaccine among citizens who have received it as part of the mass vaccination programme." Drapkina further added that the efficacy of the vaccine was more than 90 per cent.
                                    0
                                    • Denying talks of Covid-19 vaccine shortage, Crocus Medical, an organisation working with Russia's Gamaleya Research Institute of Epidemiology, has said that the clinical trial of Russia’s Sputnik V has not paused, Reuters reported.“Crocus Medical categorically denies information about the suspension of clinical trials of the Sputnik V coronavirus vaccine due to a shortage of the vaccine distributed by Reuters, citing anonymous sources in the company. This information is false, trials are ongoing, and there is sufficient vaccine supply,” Alexey Butylin, managing director of Crocus Medical, said in a statement.
                                      0
                                      • The Russian Direct Investment Fund, (RDIF), Russia's sovereign wealth fund), has submitted applications to the World Health Organization (WHO) for accelerated registration (Emergency Use Listing, EUL) and prequalification of Sputnik V, the potential Covid vaccine.
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.